AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Trial information presented on treatement for intra-abdominal infections.
2004 DEC 2 - (NewsRx.com & NewsRx.net) -- Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), recently presented exciting new phase III data about its investigational antibiotic, tigecycline, based on a clinical trial in patients with complicated intra-abdominal infections (cIAI).
This study compared tigecycline with a current empiric combination treatment for intra-abdominal infections comprised of Primaxin (Imipenem and Cilastatin for Injection), a common treatment for such illnesses. Overall, in patients who had a positive culture, the microbiologic eradication rate was 91.3% for tigecycline as a monotherapy treatment versus 89.9% for imipenem/cilastatin, with a similar safety and tolerability profile in the two groups.
This new data was presented in a late-breaking abstract at the 44th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Washington, D.C., along with additional data that compared tigecycline to vancomycin/aztreonam to treat complicated skin and skin structure infections (cSSI). A total of 21 abstracts on tigecycline were presented at this meeting.
"Serious community acquired and hospital infections are a growing public health concern around the globe," says Evan Loh, MD, vice president of cardiovascular/infectious disease at Wyeth. "These results are encouraging for the potential empiric, monotherapy use of tigecycline, one of the only new antibiotics currently in development. Once approved, this compound has the potential to have a major impact on the current treatment paradigm against infectious disease ...
- Study Describes New Once-Daily Treatment Regimen for Complicated...
- Press release article from: PR Newswire November 1, 2004 700+ words
...daily for complicated intra-abdominal infections (cIAI) was as effective as therapy...these infections.(1) Intra-abdominal infections cause significant problems in clinical...III study of complicated intra-abdominal infections, once-daily sequential therapy...
- Efficacy of Once-Daily AVELOX(R) in Treating Complicated Intra-Abdominal...
- Press release article from: PR Newswire September 29, 2006 700+ words
...treatment of complicated intra-abdominal infections (cIAI) was highlighted in two...tissue.(1) "Complicated intra-abdominal infections often involve several different...Patients with Complicated Intra- Abdominal Infections (G. Weiss, P. Reimnitz, H...
- FDA Approves New Indication for AVELOX(R) (moxifloxacin HCl) for Treatment of...
- Press release article from: PR Newswire November 30, 2005 700+ words
...treatment of complicated intra-abdominal infections (cIAI) in adults. AVELOX is the...States by Schering-Plough. Intra-abdominal infections are caused by disease, trauma or...AVELOX to treat complicated intra-abdominal infections is welcome news, providing doctors...
- Carbapenems and Other Agents that Provide Broad-Spectrum Activity are Preferred...
- Press release article from: PR Newswire May 27, 2009 700+ words
...years for the treatment of intra-abdominal infections because of their potent broad...organisms. "Treatment for intra-abdominal infections is largely empiric," stated Lisa...look for in a drug to treat intra-abdominal infections is its activity against anaerobes...
- FDA Approves New Drug to Treat Complicated Urinary Tract and Intra-Abdominal...
- Press release article from: M2 Presswire October 18, 2007 700+ words
...Complicated Urinary Tract and Intra-Abdominal Infections(C)1994-2007 M2 COMMUNICATIONS...complicated urinary tract and intra-abdominal infections. Doripenem injection, sold under...meropenem, for complicated intra-abdominal infections. The most common adverse reactions...
- Study Shows Once-Daily AVELOX(R) as Effective as Multi-Dose Combination Therapy...
- Press release article from: PR Newswire July 25, 2006 700+ words
...patients with complicated intra-abdominal infections (cIAI), according to results...important because complicated intra- abdominal infections are typically caused by mixed bacteria...hospital." Complicated intra-abdominal infections are caused by disease, trauma or...
- Doripenem clinical trials begin in complicated intra abdominal infections.
- Newspaper article from: Drug Week April 30, 2004 700+ words
...also known as S-4661), for complicated intra-abdominal infections (cIAI). Doripenem, a broad-spectrum antibiotic...carbapenems, for the treatment of complicated intra-abdominal infections is well documented. Doripenem has demonstrated many...
- Phase III Study Examines Activity of Tigecycline in Patients With Serious...
- Press release article from: PR Newswire November 3, 2004 700+ words
...clinical trial in patients with complicated intra-abdominal infections (cIAI). This study compared tigecycline with a current empiric combination treatment for intra-abdominal infections comprised of Primaxin(R) (Imipenem and Cilastatin...
Source: HighBeam Research, Trial information presented on treatement for intra-abdominal...